

## Company Overview

Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms.

## Kane Biotech Announces Granting of Options

Apr 17 2019, 4:15 PM EDT

## Kane Biotech Announces Fourth Quarter and Full Year 2018 Financial Results

Mar 25 2019, 4:15 PM EDT

## Kane Biotech Schedules Full Year 2018 Earnings Conference Call and Business Update

Mar 20 2019, 4:30 PM EDT

## Stock Overview

Symbol	KNBIF
Exchange	OTCQB
Market Cap	4.19m
Last Price	\$0.053
52-Week	\$0.04398 - \$0.08394

03/25/2019 09:44 AM EDT

## Investor Relations

Edison Advisors  
Joe Green  
Senior Vice President, Investor Relations  
1185 Avenue of the Americas  
3rd Floor  
New York, NY 10036  
T: 646-653-7030  
M: 917-575-7089  
jgreen@edisongroup.com

## Management Team

### Marc Edwards

Director, Interim Chief Executive Officer

### Ray Dupuis

Chief Financial Officer

### Gordon Guay, Ph.D.

Chief Scientific Officer

### Grant Humphrey

Vice President, Sales

### Nanda Yakandawala

Senior Research Scientist

### Wendy Nachtigall

Director, Marketing

### Andrea Gordon

Director, Regulatory and Quality Control

## Kane Biotech Inc.

162-196 Innovation Drive  
Winnipeg, Manitoba R3T 2N2  
Canada

## Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.